Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Int. braz. j. urol ; 46(3): 363-373, May-June 2020. tab, graf
Article in English | LILACS | ID: biblio-1090615

ABSTRACT

ABSTRACT Introduction: Use of androgen deprivation therapy (ADT) in carcinoma prostate (CaP) has deleterious effect on bone mineral density (BMD) leading to increase incidence of osteoporosis and skeletal-related events. We evaluated bone health status and impact of bone-directed therapy (BDT) and ADT on BMD in these patients from Jan 2015-Dec 2018. Materials and Method: Baseline bone health was assessed using Tc-99 MDP Bone scan/ DEXA scan for patients on ADT. Monthly zoledronic acid (ZA) was given to high-risk candidates (T-score ≤2.5 or previous hip/vertebral fracture) or Skel et al. metastatic patients who were receiving ADT. Baseline and follow-up (at 12-months) BMD using DEXA scan at various sites (spine, femur total, femur neck and radius) and subjective improvement in bony pain using Numeric Pain Rating Score after administration of ZA were compared. Results: A total of 96-patients of locally advanced and metastatic prostate cancer receiving ADT with or without BDT were included in the study cohort. Mean age of presentation was 68.4±15.61 years. Median serum PSA was 32.2±13.1ng/mL. There was significant improvement in mean BMD (T-score) in 64-patients post ZA therapy at 12-months (at femoral total, femoral neck and spine; 0.95, 0.79 and 0.68, respectively) (p <0.05) while there was significant deterioration in mean BMD at 12-months (at spine, femoral neck and femoral total; −0.77, −0.55 and −0.66, respectively) in 32 patients who did not receive ZA and were on ADT (p <0.05). Pain scores significantly decreased in patients after 12-months of ZA use (−2.92±2.16, p <0.01). Conclusion: Bone-directed therapy (Zoledronic acid) leads to both subjective and objective improvement in bone health of prostate cancer patients on ADT.


Subject(s)
Humans , Male , Aged , Aged, 80 and over , Prostatic Neoplasms , Bone Density , Androgen Antagonists , Tomography, X-Ray Computed , Prospective Studies , Longitudinal Studies , Middle Aged
2.
Int. braz. j. urol ; 45(5): 981-988, Sept.-Dec. 2019. tab
Article in English | LILACS | ID: biblio-1040089

ABSTRACT

ABSTRACT Objectives To compare and assess various outcomes and success of buccal mucosal graft urethroplasty (BMGU) in patients with CKD versus patients having normal renal function. Material and Methods This was a retrospective, single centre study, during period 2013 to 2017. Patients were grouped into two groups. Group 1 had patients with estimated Glomerular Filtration Rate (eGFR)>60mL/min/1.73m2 while group 2 had patients with eGFR <60mL/min/1.73m2. eGFR was calculated according to the MDRD equation. The two groups were compared with regard to various outcomes like length, location of stricture, technique of graft placement, intra-operative blood loss (haemoglobin drop), duration of hospital stay, post-operative complications and recurrence. Results A total of 223 patients were included in study with group 1 had 130 patients and group 2 had 93 patients. Mean age of patients with CKD were higher (47.49 years versus 29.13 years). The mean follow-up period was comparable between both groups (23.29 months and 22.54 months respectively). Patients with CKD had more post-operative Clavien Grade 2 or higher complications (p=0.01) and a greater recurrence rates (p<0.001) than in non-CKD patients. On multivariate analysis, age and CKD status was significant predictor of urethroplasty success (p=0.004) (OR= 14.98 (1.952-114.94, 95% CI). Conclusions CKD patients are more prone to post-operative complications in terms of wound infection, graft uptake and graft failure and higher recurrence rates following BMGU.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Young Adult , Urologic Surgical Procedures/methods , Urethra/surgery , Urethral Stricture/surgery , Renal Insufficiency, Chronic/physiopathology , Mouth Mucosa/transplantation , Postoperative Complications/etiology , Recurrence , Urologic Surgical Procedures/adverse effects , Multivariate Analysis , Retrospective Studies , Risk Factors , Treatment Outcome , Renal Insufficiency, Chronic/complications , Glomerular Filtration Rate , Middle Aged
3.
Int. braz. j. urol ; 45(4): 765-774, July-Aug. 2019. tab, graf
Article in English | LILACS | ID: biblio-1019890

ABSTRACT

ABSTRACT Objectives To primarily evaluate the functional outcomes of PCNL for bilateral renal calculi/calculi in solitary functioning kidney with Chronic Kidney Disease(CKD). To identify factors affecting the renal replacement therapy following PCNL. Materials and Methods Patients with bilateral renal calculi/calculi in solitary kidney and CKD (eGFR<60/s.creatinine>2) and Good Performance Status [Eastern Cooperative Oncology Group (ECOG): 0-2] were included in the study. Results A total of 60 patients with CKD who had bilateral renal calculi/calculi in solitary functioning kidney underwent PCNL. At 6 months, eGFR improved or stabilized in 45 (75%) patients, while in 15 (25%) patients eGFR deteriorated. A total of 5 (14.28%) and 2 (25%) patients of CKD stage 4 and 5 respectively had improvement in eGFR as well as CKD stage. Fourteen (82.35%), 21 (60%), 3 (37.5%) patients of CKD stage 3, 4, 5 had improvement in eGFR but not significant enough to cause stage migration. Again 3 (17.65%) , 9 ( 40%) and 3 (37.5%) patients of CKD stage 3, 4, 5 had reduction in eGFR but not significant enough to cause stage migration. None of the patients had worsening of CKD stage. Preoperative CKD stage and eGFR were compared with measurements made at the final follow up visit (6 months). Conclusion Our results indicate that most patients of renal calculi with CKD show improvement or stabilization of renal function with aggressive stone removal. Improvement is more in patients who have mild to moderate CKD. Aggressive management of comorbidities, peri-operative UTI and complications may delay or avoid progression of CKD status in such patients.


Subject(s)
Humans , Male , Female , Child , Adolescent , Adult , Aged , Young Adult , Kidney Calculi/surgery , Renal Insufficiency, Chronic/surgery , Nephrolithotomy, Percutaneous/methods , Postoperative Complications/etiology , Time Factors , Severity of Illness Index , Kidney Calculi/physiopathology , Feasibility Studies , Prospective Studies , Reproducibility of Results , Risk Factors , Follow-Up Studies , Urinalysis , Treatment Outcome , Creatinine/blood , Renal Insufficiency, Chronic/physiopathology , ErbB Receptors/blood , Nephrolithotomy, Percutaneous/adverse effects , Glomerular Filtration Rate , Middle Aged
4.
Article in English | IMSEAR | ID: sea-140066

ABSTRACT

Aim: The aim of the study is to assess and compare the cytotoxicity of commercially available four denture adhesives ex-vivo. Materials and Methods: Four commercially available denture adhesives namely Metrodent powder, Fixon powder, Dentiro powder and Fixon cream were selected. Normal saline was used in control group. To evaluate the cytotoxicity of denture adhesives, macrophages were isolated from peritoneal cavity of Swiss albino mice and cell integrity/cell viability method was done by using trypan blue dye. Results: Viable cells were counted and subjected to statistical analysis. ANOVA, F and 't' test were performed, which showed statistically significant values (P < 0.001). The mean percentage of viable cells was highest in the control group (95%) and lowest in Fixon powder (55.66%), with Dentiro powder the mean percentage of viable cells was 63.66%, with Metrodent powder 67.6% while with Fixon cream it was 69.33%. Conclusion: All tested denture adhesives showed varied degree of cytotoxicity that is statistically significant. The degree of toxicity was more in Fixon powder followed by Dentiro powder and Metrodent powder with least in Fixon cream.


Subject(s)
Adhesives/toxicity , Animals , Cell Count , Cell Separation , Cell Survival/drug effects , Cells, Cultured , Coloring Agents/diagnosis , Denture Retention , Macrophages, Peritoneal/drug effects , Materials Testing , Mice , Trypan Blue/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL